TMBR
TMBR company profile
Latest price
As of — · Market data by Massive
Market cap
—
Volume
—
Previous close
—
Day range
—
Listed
—
Coverage
34 articles
Price performance
Recent trading
Newsroom
Latest TMBR coverage
Timber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing Compliance
[ad_1] WARREN, NJ – (NewMediaWire) – September 18, 2023 – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the NYSE American LLC (the “NYSE A
Timber Pharmaceuticals Discloses Communication From NYSE American
[ad_1] WARREN, NJ – (NewMediaWire) – July 03, 2023 – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that on June 28, 2023 it received a letter (
Pre-Market Movers 6/5/2023
Frasca International Inc. (FRZA) is having a significant day in pre-market trading with a massive increase of 136.9%. The volume of shares being traded is impressive at approximately 8,486,000. Timber Pharmaceuticals Inc. (TMBR) is showing a robust performance, gaining 86.6% in the pre-market session. The trading volume currently stands at about 2,454,000 sh
Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2022 Financial Results
[ad_1] – Lead asset TMB-001 is only compound to receive official orphan drug designation from European Commission for two severe subtypes of congenital ichthyosis, ARCI and XLRI – – Timber has enrolled 50% of patients for pivotal TMB-001 Phase 3 ASCEND clinical trial – WARREN, NJ – (NewMediaWire) – March 31, 2023 – T
Timber Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards
[ad_1] BASKING RIDGE, NJ – (NewMediaWire) – December 09, 2022 – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the Company has received for
Timber Pharmaceuticals Announces Halt of Common Stock Trading
[ad_1] Compliance with NYSE Listing Requirements Contingent on Stockholder Approval of Reverse Stock Split at Special Meeting of Stockholders on November 7, 2022 and Consummation of Reverse Stock Split BASKING RIDGE, NJ – (NewMediaWire) – November 3, 2022 – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a
Timber Pharmaceuticals Announces Notification of NYSE American Continued Listing Deficiency
[ad_1] BASKING RIDGE, NJ – (NewMediaWire) – August 29, 2022 – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it had received a deficiency l
Timber Pharmaceuticals Announces Publication of Results from Phase 2b CONTROL Study of FDA-Designated Breakthrough Therapy TMB-001 in the Journal of the American Academy of Dermatology
[ad_1] – Previously reported study demonstrated clinically meaningful efficacy with a favorable safety profile for TMB-001 in moderate to severe congenital ichthyosis – – Company has since initiated pivotal Phase 3 ASCEND clinical trial – BASKING RIDGE, NJ – (NewMediaWire) – August 26, 2022 – Timber Pharmaceuticals,
Timber Pharmaceuticals Provides Business Update and Announces Second Quarter 2022 Financial Results
[ad_1] Timber Enrolls First Patients in Phase 3 ASCEND Clinical Trial after Receiving Breakthrough Designation from FDA for Lead Asset TMB-001 BASKING RIDGE, NJ – (NewMediaWire) – August 11, 2022 – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and comme
Timber Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
[ad_1] Basking Ridge, NJ – (NewMediaWire) – August 4, 2022 – Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced the pricing of a public offering of 66,666,667 shar
Timber Pharmaceuticals Announces First Patients Enrolled in Phase 3 ASCEND Clinical Trial Evaluating TMB-001 in Congenital Ichthyosis
[ad_1] Pivotal Trial Expected to Enroll More Than 140 Patients With Moderate to Severe Congenital Ichthyosis at Leading Research Centers in the U.S., Canada, Italy, France, and Germany BASKING RIDGE, NJ – (NewMediaWire) – June 23, 2022 – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biophar
Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2022 Financial Results
[ad_1] Lead Asset TMB-001 Receives Fast Track Designation in Advance of Phase 3 Study Initiation by June 30th, 2022 BASKING RIDGE, NJ – (NewMediaWire) – May 12, 2022 – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments fo
Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2021 Financial Results
[ad_1] Company Plans to Initiate Phase 3 Study for TMB-001 in Q2 2022 BASKING RIDGE, NJ – (NewMediaWire) – March 31, 2022 – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, toda
Timber Pharmaceuticals Announces Late-Breaking Presentation at the American Academy of Dermatology 2022 Annual Meeting
[ad_1] Sub-analysis of the Phase 2b CONTROL study in congenital ichthyosis demonstrates treatment success with TMB-001 regardless of subtype – BASKING RIDGE, NJ – (NewMediaWire) – March 25, 2022 – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and
Timber Pharmaceuticals Announces Closing of Exercise of Underwriter's Option to Purchase Additional Common Stock
[ad_1] Underwritten Public Offering Resulted in Total Gross Proceeds of $17.25 Million Basking Ridge, NJ – (NewMediaWire) – November 09, 2021 – Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermato
Timber Pharmaceuticals Announces Closing of $15 Million Public Offering
[ad_1] Basking Ridge, NJ – (NewMediaWire) – November 05, 2021 – Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced the closing of its previously announced underwri
Timber Pharmaceuticals Reports Positive Top-line Results from Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital Ichthyosis
[ad_1] Timber Pharmaceuticals Reports Positive Top-line Results from Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital Ichthyosis · Data demonstrate reduction in targeted and overall severity of CI in patients treated with topical IPEG™ TMB-001 (topical isotretinoin) · Company planning for end-of-Phase 2 meeting with FDA i
Timber Pharmaceuticals Presents at EADV's 30th Anniversary Congress
[ad_1] Basking Ridge, NJ – (NewMediaWire) – October 01, 2021 – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it is presenting at the European Academy of
Timber Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
[ad_1] Basking Ridge, NJ – (NewMediaWire) – September 10, 2021 – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it will present at the H.C. Wainwright 23r
Timber Pharmaceuticals Announces Adjournment of Annual Meeting
[ad_1] Basking Ridge, NJ – (NewMediaWire) – June 03, 2021 – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that on June 3, 2021 its 2021 An
Timber Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2b CONTROL Study Evaluating TMB-001 in Congenital Ichthyosis
[ad_1] – Company plans to ask for end-of-Phase 2 meeting with FDA by end of 2021 – Basking Ridge, N.J. – (NewMediaWire) – May 26, 2021 – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments fo
Timber Pharmaceuticals Announces Appointment of John Koconis as Chairman of the Board of Directors
[ad_1] – Edward J. Sitar appointed as Lead Independent Director of the Board – – Company establishes Science and Technology Committee to be chaired by Dr. David Cohen – Basking Ridge, NJ – (NewMediaWire) – April 23, 2021 – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceut
Timber Pharmaceuticals Sets Record Date for Annual Meeting of Shareholders and ProvidesUpdate on Its Annual Filings
[ad_1] Basking Ridge, NJ – (NewMediaWire) – April 02, 2021 – Timber Pharmaceuticals, Inc. (NYSE American: TMBR) ("Timber” or the "Company"), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that its Annual Meeting of Shareholders will be hel
Timber Pharmaceuticals Announces 50% Enrollment in Phase 2b CONTROL Study in Congenital Ichthyosis
[ad_1] – Study is Evaluating TMB-001 (Topical Isotretinoin) in Subtypes of Rare Genetic Keratinization Disorder – Company Awarded Final Tranche of $1.5 million FDA Orphan Products Clinical Trials Grant WOODCLIFF LAKE, NJ – (NewMediaWire) – March 15, 2021 – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE Americ
Timber Pharmaceuticals Announces Presentation at 2021 H.C. Wainwright Global Life Sciences Conference
[ad_1] WOODCLIFF LAKE, NJ – (NewMediaWire) – March 05, 2021 – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that Timber’s Chief Executive Officer John Koconis
Timber Pharmaceuticals Appoints Alan Mendelsohn, M.D., as Chief Medical Officer
[ad_1] Dr. Mendelsohn has 20+ Years’ Experience in Clinical Development and Medical Affairs WOODCLIFF LAKE, NJ – (NewMediaWire) – January 25, 2021 – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatmen
Timber Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for TMB-003 for the Treatment of Systemic Sclerosis
[ad_1] Timber Expects to Submit Investigational New Drug (IND) Application to the FDA in 2022 WOODCLIFF LAKE, N.J. – (NewMediaWire) – January 12, 2021 – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatment
Timber Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for Lead Asset TMB-001
[ad_1] – Formal notice confirms intent to grant patent for pharmaceutical isotretinoin composition – WOODCLIFF LAKE, NJ – (NewMediaWire) – December 15, 2020 – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments
Timber Pharmaceuticals Hosts Business Update Conference Call
[ad_1] Call to be held on Thursday, December 17th at 11:00am EST WOODCLIFF LAKE, NJ – (NewMediaWire) – December 10, 2020 – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today
Timber Pharmaceuticals to Present at the 13th Annual LD Micro Main Event Conference
[ad_1] Presentation on Tuesday December 15th at 10:40am EST LOS ANGELES, CA – (NewMediaWire) – December 08, 2020 – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatolog
Timber Pharmaceuticals Signs Waiver Agreement with Warrant Holders
[ad_1] WOODCLIFF LAKE, NJ – (NewMediaWire) – November 20, 2020 – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it has signed waiver agreements with certa
Timber Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference
[ad_1] Virtual Presentation on Wednesday, September 16th at 12:30 PM ET WOODCLIFF LAKE, NJ, – (NewMediaWire) – September 11, 2020 — Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases, today
Timber Pharmaceuticals Announces Appointment of Dr. David Cohen and Dr. Lubor Gaal to Board of Directors
[ad_1] WOODCLIFF LAKE, NJ – (NewMediaWire) – August 19, 2020 – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases, today announced the appointment of David Cohen, M.D. and Lu
Timber Pharmaceuticals Provides Business Update and Announces Second Quarter 2020 Financial Results
[ad_1] Phase 2b Clinical Trials for Each of the Company’s Lead Assets in Orphan Dermatologic Diseases are Progressing as Planned WOODCLIFF LAKE, NJ – (NewMediaWire) – August 18, 2020 – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development an